Literature DB >> 29951508

Can we exonerate GLP-1 receptor agonists from blame for adverse pancreatic events?

Conor F Murphy1, Carel W le Roux1,2.   

Abstract

Entities:  

Year:  2018        PMID： 29951508      PMCID： PMC5994527          DOI： 10.21037/atm.2018.03.06

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.

Authors:  William M Steinberg; John B Buse; Marie Louise Muus Ghorbani; David D Ørsted; Michael A Nauck
Journal:  Diabetes Care       Date:  2017-05-05       Impact factor: 19.112

Review 2.  Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.

Authors:  Heidi Storgaard; Frederik Cold; Lise L Gluud; Tina Vilsbøll; Filip K Knop
Journal:  Diabetes Obes Metab       Date:  2017-03-17       Impact factor: 6.577

3.  3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.

Authors:  Carel W le Roux; Arne Astrup; Ken Fujioka; Frank Greenway; David C W Lau; Luc Van Gaal; Rafael Violante Ortiz; John P H Wilding; Trine V Skjøth; Linda Shapiro Manning; Xavier Pi-Sunyer
Journal:  Lancet       Date:  2017-02-23       Impact factor: 79.321

4.  GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.

Authors:  Charles Pyke; R Scott Heller; Rikke K Kirk; Cathrine Ørskov; Steffen Reedtz-Runge; Peter Kaastrup; Anders Hvelplund; Linda Bardram; Dan Calatayud; Lotte Bjerre Knudsen
Journal:  Endocrinology       Date:  2014-01-27       Impact factor: 4.736

5.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

Authors:  Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding
Journal:  N Engl J Med       Date:  2015-07-02       Impact factor: 91.245

6.  Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Authors:  Belinda Gier; Aleksey V Matveyenko; David Kirakossian; David Dawson; Sarah M Dry; Peter C Butler
Journal:  Diabetes       Date:  2012-01-20       Impact factor: 9.461

Review 7.  The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.

Authors:  Jessica E Potts; Laura J Gray; Emer M Brady; Kamlesh Khunti; Melanie J Davies; Danielle H Bodicoat
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse
Journal:  N Engl J Med       Date:  2016-06-13       Impact factor: 176.079

9.  Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.

Authors:  Laurent Azoulay; Kristian B Filion; Robert W Platt; Matthew Dahl; Colin R Dormuth; Kristin K Clemens; Madeleine Durand; David N Juurlink; Laura E Targownik; Tanvir C Turin; J Michael Paterson; Pierre Ernst
Journal:  BMJ       Date:  2016-02-17

10.  Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.

Authors:  Han Chen; Xiaoying Zhou; Tao Chen; Bingtuan Liu; Wujuan Jin; Huiyuan Gu; Tianyuan Hong; Guoxin Zhang
Journal:  Diabetes Ther       Date:  2016-09-21       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.